<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFOTAN- cefotetan disodiumÂ injectionÂ </strong><br>AstraZeneca Pharmaceuticals, LP<br></p></div>
<h1>CEFOTANÂ®<br>cefotetan disodium for injection<br>FOR INTRAVENOUS OR INTRAMUSCULAR USE<br>CEFOTANÂ®<br>cefotetan injection<br>FOR INTRAVENOUS USE ONLY</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1>In GALAXYÂ®  Plastic Container (PL 2040)</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOTAN and other antibacterial drugs, CEFOTAN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CEFOTAN (cefotetan disodium for injection) and CEFOTAN (cefotetan injection) in Galaxy<span class="Sup">Â®</span> * plastic container (PL 2040) as cefotetan disodium are sterile, semisynthetic, broad-spectrum, beta-lactamase resistant, cephalosporin (cephamycin) antibiotics for parenteral administration. It is the disodium salt of [6R-(6Î±,7Î±)]-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1<span class="Italics">H</span>-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Its molecular formula is</p>
<p>C<span class="Sub">17</span>H<span class="Sub">15</span>N<span class="Sub">7</span>Na<span class="Sub">2</span>O<span class="Sub">8</span>S<span class="Sub">4</span> with a molecular weight of 619.57.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Structural Formula</h2>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-chemicalstructure.jpg"></div>
<p class="First">CEFOTAN (cefotetan disodium for injection) is supplied in vials containing 80 mg (3.5 mEq) of sodium per gram of cefotetan activity. It is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder which is very soluble in water. Reconstituted solutions of CEFOTAN (cefotetan disodium for injection) are intended for intravenous and intramuscular administration. The solution varies from colorless to yellow depending on the concentration. The pH of freshly reconstituted solutions is usually between 4.5 to 6.5.</p>
<p>CEFOTAN in the ADD-Vantage Vialâ€  is intended for intravenous use only after dilution with the appropriate volume of ADD-Vantage diluent solution.</p>
<p>CEFOTAN is available in two vial strengths. Each CEFOTAN 1 g vial contains cefotetan disodium equivalent to 1 g cefotetan activity. Each CEFOTAN 2 g vial contains cefotetan disodium equivalent to 2 g cefotetan activity.</p>
<p>CEFOTAN (cefotetan injection) in the Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) is a frozen, iso-osmotic, sterile, nonpyrogenic premixed 50 mL solution containing 1 g or 2Â g cefotetan as sterile cefotetan disodium. Dextrose, USP has been added to adjust the <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> to 300 mOsmol/kg (approximately 1.9 g and 1.1 g to the 1 g and 2Â g dosages, respectively); sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> has been added to convert cefotetan free acid to the sodium salt. The pH has been adjusted between 4 and 6.5 with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and may have been adjusted with hydrochloric acid. CEFOTAN (cefotetan injection) in the Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) contains 80 mg (3.5 mEq) of sodium per gram of cefotetan activity. After thawing to room temperature, the solution is intended for intravenous use only.</p>
<p>This Galaxy<span class="Sup">Â®</span> container is fabricated from a specially designed multilayer plastic (PL 2040). Solutions are in contact with the polyethylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration dating period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers as well as by tissue culture toxicity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">High plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers.</p>
<table frame="below">
<caption><span>PLASMA CONCENTRATIONS AFTER 1 GRAM IV<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> OR IM DOSE</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot>
<tr class="First Last"><td align="center" colspan="8" valign="top"></td></tr>
<tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>30-minute infusion</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="8" valign="top">
<p class="First"><span class="Bold">Mean Plasma Concentration (Î¼g/mL)</span></p>
<p><span class="Bold">Time After Injection</span></p>
</td></tr>
<tr>
<td align="center" valign="top"><p class="First"><span class="Bold">Route</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">15 min</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">30 min</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">1h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">2h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">4h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">8h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">12h</span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">IV</p></td>
<td align="center" valign="top"><p class="First">92</p></td>
<td align="center" valign="top"><p class="First">158</p></td>
<td align="center" valign="top"><p class="First">103</p></td>
<td align="center" valign="top"><p class="First">72</p></td>
<td align="center" valign="top"><p class="First">42</p></td>
<td align="center" valign="top"><p class="First">18</p></td>
<td align="center" valign="top"><p class="First">9</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">IM</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">56</p></td>
<td align="center" valign="top"><p class="First">71</p></td>
<td align="center" valign="top"><p class="First">68</p></td>
<td align="center" valign="top"><p class="First">47</p></td>
<td align="center" valign="top"><p class="First">20</p></td>
<td align="center" valign="top"><p class="First">9</p></td>
</tr>
</tbody>
</table>
<p></p>
<table frame="below">
<caption><span>PLASMA CONCENTRATIONS AFTER 2 GRAM IV<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> OR IM DOSE</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot>
<tr class="First"><td align="center" colspan="8" valign="top"></td></tr>
<tr class="Last"><td align="center" colspan="8" valign="top"></td></tr>
<tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Injected over 3 minutes</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Concentrations estimated from regression line</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="8" valign="top">
<p class="First"><span class="Bold">Mean Plasma Concentration (Î¼g/mL)</span></p>
<p><span class="Bold">Time After Injection</span></p>
</td></tr>
<tr>
<td align="center" valign="top"><p class="First"><span class="Bold">Route</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">5 min</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">10 min</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">1h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">3h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">5h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">9h</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">12h</span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">IV</p></td>
<td align="center" valign="top"><p class="First">237</p></td>
<td align="center" valign="top"><p class="First">223</p></td>
<td align="center" valign="top"><p class="First">135</p></td>
<td align="center" valign="top"><p class="First">74</p></td>
<td align="center" valign="top"><p class="First">48</p></td>
<td align="center" valign="top"><p class="First">22</p></td>
<td align="center" valign="top"><p class="First">12<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a></p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">IM</p></td>
<td align="center" valign="top"><p class="First">--</p></td>
<td align="center" valign="top"><p class="First">20</p></td>
<td align="center" valign="top"><p class="First">75</p></td>
<td align="center" valign="top"><p class="First">91</p></td>
<td align="center" valign="top"><p class="First">69</p></td>
<td align="center" valign="top"><p class="First">33</p></td>
<td align="center" valign="top"><p class="First">19</p></td>
</tr>
</tbody>
</table>
<p>The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either intravenous or intramuscular administration.</p>
<p>Repeated administration of CEFOTAN does not result in</p>
<p>accumulation of the drug in normal subjects.</p>
<p>Cefotetan is 88% plasma protein bound.</p>
<p>No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.</p>
<p>In normal patients, from 51% to 81% of an administered dose of CEFOTAN is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations. Following intravenous doses of 1 gram and 2 grams, urinary concentrations are highest during the first hour and reach concentrations of approximately 1700 and 3500 Âµg/mL respectively.</p>
<p>In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged. The mean terminal half-life increases with declining renal function, from approximately 4 hours in volunteers with normal renal function to about 10 hours in those with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There is a linear correlation between the systemic clearance of cefotetan and creatinine clearance. When renal function is impaired, a reduced dosing schedule based on creatinine clearance must be used. (see <a href="#barberpj1136224293579">DOSAGE AND ADMINISTRATION</a>).</p>
<p>In pharmacokinetics studies of eight elderly patients (greater than 65 years) with normal renal function and six healthy volunteers (aged 25 to 28 years), mean (Â± 1sd) Total Body Clearance (1.8(0.1) L/h vs. 1.8 (0.3) L/h) and mean Volume of Distribution (10.4(1.2) L vs. 10.3 (1.6)L) were similar following administration of a one gram intravenous bolus dose.</p>
<p>Therapeutic levels of cefotetan are achieved in many body tissues and fluids including:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First">skin</p></td>
<td align="center" valign="top"><p class="First">ureter</p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First">muscle</p></td>
<td align="center" valign="top"><p class="First">bladder</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">fat</p></td>
<td align="center" valign="top"><p class="First">maxillary sinus mucosa</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">myometrium</p></td>
<td align="center" valign="top"><p class="First">tonsil</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">endometrium</p></td>
<td align="center" valign="top"><p class="First">bile</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">cervix</p></td>
<td align="center" valign="top"><p class="First">peritoneal fluid</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">ovary</p></td>
<td align="center" valign="top"><p class="First">umbilical cord serum</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">kidney</p></td>
<td align="center" valign="top"><p class="First">amniotic fluid</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The bactericidal action of cefotetan results from inhibition of cell wall synthesis. Cefotetan has <span class="Italics">in vitro</span> activity against a wide range of aerobic and anaerobic gram-positive and gram-negative organisms. The methoxy group in the 7-alpha position provides cefotetan with a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinases of gram-negative bacteria.</p>
<p>Cefotetan has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms <span class="Bold">both </span><span class="Bold Italics">in vitro</span><span class="Bold"> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <a href="#barberpj1136224322517">INDICATIONS AND USAGE</a>)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Gram-Negative Aerobes</h2>
<p class="First"><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Haemophilus influenzae</span> (including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Klebsiella species</span> (including <span class="Italics">K. pneumoniae</span>)</p>
<p><span class="Italics">Morganella morganii</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span> (nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Providencia rettgeri</span></p>
<p><span class="Italics">Serratia marcescens</span></p>
<p><span class="Bold">NOTE:  </span>Approximately one-half of the usually clinically significant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter species</span> (eg, <span class="Italics">E.Â aerogenes</span> and <span class="Italics">E. cloacae</span>) are resistant to cefotetan. Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span> and <span class="Italics">Acinetobacter</span> species are resistant to cefotetan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>Gram-Positive Aerobes</h2>
<p class="First"><span class="Italics">Staphylococcus aureus</span> (including penicillinase- and</p>
<p>nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Streptococcus agalactiae</span> (group B beta-hemolytic streptococcus)</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">NOTE:  </span>Methicillin-resistant staphylococci are resistant to cephalosporins. Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus epidermidis</span> and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, eg, <span class="Italics">Enterococcus faecalis</span> (formerly <span class="Italics">Streptococcus faecalis</span>) are resistant to cefotetan</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Anaerobes</h2>
<p class="First"><span class="Italics">Prevotella bivia</span> (formerly <span class="Italics">Bacteroides bivius</span>)</p>
<p><span class="Italics">Prevotella disiens</span> (formerly <span class="Italics">Bacteroides disiens</span>)</p>
<p><span class="Italics">Bacteroides fragilis</span></p>
<p><span class="Italics">Prevotella melaninogenica </span>(formerly <span class="Italics">Bacteroides</span></p>
<p><span class="Italics">melaninogenicus</span>)</p>
<p><span class="Italics">Bacteroides vulgatus</span></p>
<p><span class="Italics">Fusobacterium species</span></p>
<p>Gram-positive bacilli (including <span class="Italics">Clostridium</span> species; see<a href="#barberpj1136224340751">WARNINGS</a>)</p>
<p><span class="Bold">NOTE:</span> Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> are resistant (see <a href="#barberpj1136224340751">WARNINGS</a>).</p>
<p><span class="Italics">Peptococcus niger</span></p>
<p><span class="Italics">Peptostreptococcus species</span></p>
<p><span class="Bold">NOTE:  </span>Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">B. distasonis</span>, <span class="Italics">B. ovatus</span> and <span class="Italics">B.Â thetaiotaomicron</span> are resistant to cefotetan <span class="Italics">in vitro</span>. However, the therapeutic utility of cefotetan against these organisms cannot be accurately predicted on the basis of <span class="Italics">inÂ vitro</span> susceptibility tests alone.</p>
<p>The following <span class="Italics">in vitro</span> data are available but their clinical significance is unknown. Cefotetan has been shown to be active <span class="Italics">in vitro </span>against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>Gram-Negative Aerobes</h2>
<p class="First"><span class="Italics">Citrobacter species</span> (including <span class="Italics">C. diversus </span>and <span class="Italics">C. freundii</span>)</p>
<p><span class="Italics">Klebsiella oxytoca</span></p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span> (penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> species</p>
<p><span class="Italics">Serratia </span>species</p>
<p><span class="Italics">Shigella </span>species</p>
<p><span class="Italics">Yersinia</span> enterocolitica</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>Anaerobes</h2>
<p class="First"><span class="Italics">Porphyromonas asaccharolytica</span> (formerly <span class="Italics">Bacteroides</span></p>
<p><span class="Italics">asaccharolyticus</span>)</p>
<p><span class="Italics">Prevotella oralis </span>(formerly <span class="Italics">Bacteroides oralis</span>)</p>
<p><span class="Italics">Bacteroides splanchnicus</span></p>
<p><span class="Italics">Clostridium difficile</span> (see <a href="#barberpj1136224340751">WARNINGS</a>)</p>
<p><span class="Italics">Propionibacterium</span> species</p>
<p><span class="Italics">Veillonella</span> species</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First"><span class="Bold">Dilution Techniques:</span> Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICâ€™s). These MICâ€™s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations or cefotetan powder. The MIC values should be interpreted according to the following criteria:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td valign="top"><p class="First"><span class="Bold">MIC (Î¼g/mL)</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Interpretation</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First">â‰¤Â 16</p></td>
<td align="center" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">32</p></td>
<td align="center" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">â‰¥Â 64</p></td>
<td align="center" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p>A report of â€˜Susceptibleâ€™ indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€˜Intermediateâ€™ indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€˜Resistantâ€™ indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard cefotetan powder should provide the following MIC values:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First"><span class="Bold">Microorganism</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">MIC (Î¼g/mL)</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First"><span class="Italics">E. coli</span> ATCC 25922</p></td>
<td align="center" valign="top"><p class="First">0.06-0.25</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First"><span class="Italics">S. aureus</span> ATCC 29213</p></td>
<td align="center" valign="top"><p class="First">4-16</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Diffusion Techniques:</span> Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2 </span>requires the use of the standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 Î¼g cefotetan to test the susceptibility of microorganisms to cefotetan.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 Âµg cefotetan disk should be interpreted according to the following criteria:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First"><span class="Bold">Zone Diameter (mm)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Interpretation</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First">â‰¥Â 16</p></td>
<td align="center" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">13-15</p></td>
<td align="center" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">â‰¤Â 12</p></td>
<td align="center" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefotetan. </p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 Î¼g cefotetan disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First"><span class="Bold">Microorganism</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Zone Diameter (mm)</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First"><span class="Italics">E. coli</span> ATCC 25922</p></td>
<td align="center" valign="top"><p class="First">28-34</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First"><span class="Italics">S. aureus</span> ATCC 25923</p></td>
<td align="center" valign="top"><p class="First">17-23</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Anaerobic Techniques: </span>For anaerobic bacteria, the susceptibility to cefotetan as MICâ€™s can be determined by standardized test methods<span class="Sup">3</span>. The MIC values obtained should be interpreted according to the following criteria:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First"><span class="Bold">MIC (Âµg/mL)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Interpretation</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First">â‰¤Â 16</p></td>
<td align="center" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">32</p></td>
<td align="center" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">â‰¥Â 64</p></td>
<td align="center" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p>Interpretation is identical to that stated above for results using dilution techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures. Standardized cefotetan powder should provide the following MIC values:</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="center" valign="top"><p class="First"><span class="Bold">Microorganism</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">MIC (Âµg/mL)</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top"><p class="First"><span class="Italics">Bacteroides fragilis </span>ATCC 25285</p></td>
<td align="center" valign="top"><p class="First">4-16</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First"><span class="Italics">Bacteroides thetaiotaomicron</span> ATCC 29741</p></td>
<td align="center" valign="top"><p class="First">32-128</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First"><span class="Italics">Eubacterium lentum</span> ATCC 43055</p></td>
<td align="center" valign="top"><p class="First">32-128</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="barberpj1136224322517"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOTAN and other antibacterial drugs, CEFOTAN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">CEFOTAN is indicated for the therapeutic treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<h3>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella </span>spp (including <span class="Italics">K. pneumoniae</span>), <span class="Italics">Proteus mirabilis</span> and <span class="Italics">Proteus</span> spp (which may include the organisms now called <span class="Italics">Proteus vulgaris</span>, <span class="Italics">Providencia rettgeri</span>, and <span class="Italics">Morganella morganii</span>).</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<h3>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span></span> caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Staphylococcus aureus</span> (penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Haemophilus influenzae</span> (including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Klebsiella</span> species (including <span class="Italics">K. pneumoniae</span>), <span class="Italics">E.Â coli</span>, <span class="Italics">Proteus mirabilis</span>, and <span class="Italics">Serratia marcescens</span>*.</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.3"></a><p></p>
<h3>
<span class="Bold">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> due to <span class="Italics">Staphylococcus aureus</span> (penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus </span>species (excluding enterococci), <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella pneumoniae</span>, <span class="Italics">Peptococcus niger</span>*, <span class="Italics">Peptostreptococcus</span> species.</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.4"></a><p></p>
<h3>
<span class="Bold">Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span>, (including penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Streptococcus</span> species (excluding enterococci), <span class="Italics">Streptococcus agalactiae</span>, <span class="Italics">E. coli</span>, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Neisseria gonorrhoeae</span>, <span class="Italics">Bacteroides</span> species (excluding <span class="Italics">B.Â distasonis</span>, <span class="Italics">B. ovatus</span>, <span class="Italics">B. thetaiotaomicron</span>), <span class="Italics">Fusobacterium</span> species*, and gram-positive anaerobic cocci (including <span class="Italics">Peptococcus niger</span> and <span class="Italics">Peptostreptococcus species</span>).</h3>
<p class="First">Cefotetan, like other cephalosporins, has no activity against</p>
<p><span class="Italics">Chlamydia trachomatis</span>. Therefore, when cephalosporins are used in the treatment of <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>, and <span class="Italics">C. trachomatis</span> is one of the suspected pathogens, appropriate antichlamydial coverage should be added.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.5"></a><p></p>
<h3>
<span class="Bold">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span></span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella</span> species (including <span class="Italics">K. pneumoniae</span>), <span class="Italics">Streptococcus</span> species (excluding enterococci), <span class="Italics">Bacteroides </span>species (excluding <span class="Italics">B. distasonis</span>, <span class="Italics">B. ovatus</span>, <span class="Italics">B.Â thetaiotaomicron</span>) and <span class="Italics">Clostridium</span> species*.</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.6"></a><p></p>
<h3>
<span class="Bold">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span>.*</h3>
<p class="First">*Efficacy for this organism in this organ system was studied in fewer than ten <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to cefotetan. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.</p>
<p>In cases of confirmed or suspected gram-positive or gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or in patients with other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in which the causative organism has not been identified, it is possible to use CEFOTAN concomitantly with an aminoglycoside. Cefotetan combinations with aminoglycosides have been shown to be synergistic <span class="Italics">in vitro</span> against many Enterobacteriaceae and also some other gram-negative bacteria. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patient's condition.</p>
<p><span class="Bold">NOTE:  </span>Increases in serum creatinine have occurred when CEFOTAN was given alone. If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may be potentiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Prophylaxis</h2>
<p class="First">The preoperative administration of CEFOTAN may reduce the incidence of certain <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span> in patients undergoing surgical procedures that are classified as clean contaminated or potentially contaminated (eg, cesarean section, abdominal or vaginal hysterectomy, transurethral surgery, biliary tract surgery, and gastrointestinal surgery). </p>
<p>If there are signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for culture should be obtained for identification of the causative organism so that appropriate therapeutic measures may be initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="barberpj1136224375361"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CEFOTAN is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics and in those individuals who have experienced a cephalosporin associated <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="barberpj1136224340751"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH CEFOTAN IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFOTETAN DISODIUM, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFOTAN OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</p>
<p>AN IMMUNE MEDIATED <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> HAS BEEN OBSERVED IN PATIENTS RECEIVING CEPHALOSPORIN CLASS ANTIBIOTICS. SEVERE CASES OF <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span>, INCLUDING FATALITIES, HAVE BEEN REPORTED IN ASSOCIATION WITH THE ADMINISTRATION OF CEFOTETAN. SUCH REPORTS ARE UNCOMMON.  THERE APPEARS TO BE AN INCREASED RISK OF DEVELOPING <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> ON CEFOTETAN RELATIVE TO OTHER CEPHALOSPORINS OF AT LEAST 3 FOLD. IF A PATIENT DEVELOPS <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span> ANYTIME WITHIN 2-3 WEEKS SUBSEQUENT TO THE ADMINISTRATION OF CEFOTETAN, THE DIAGNOSIS OF A CEPHALOSPORIN ASSOCIATED <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span> SHOULD BE CONSIDERED AND THE DRUG STOPPED UNTIL THE ETIOLOGY IS DETERMINED WITH CERTAINTY. BLOOD TRANSFUSIONS MAY BE CONSIDERED AS NEEDED (See <span class="Bold"><a href="#barberpj1136224375361">CONTRAINDICATIONS</a></span>).</p>
<p>PATIENTS WHO RECEIVE COURSES OF CEFOTETAN FOR THE TREATMENT OR PROPHYLAXIS OF <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> SHOULD HAVE PERIODIC MONITORING FOR SIGNS AND SYMPTOMS OF <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> INCLUDING A MEASUREMENT OF HEMATOLOGICAL PARAMETERS WHERE APPROPRIATE. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including cefotetan, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile </span>is a primary cause of â€œantibiotic-associated colitisâ€?.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, appropriate therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. (See <a href="#barberpj1136224399158">ADVERSE REACTIONS</a>.)</p>
<p>In common with many other broad-spectrum antibiotics, CEFOTAN may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity and, possibly, subsequent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Those at increased risk include patients with renal or hepatobiliary impairment or poor nutritional state, the elderly, and patients with cancer. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored and exogenous vitamin K administered as indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General:</h2>
<p class="First">Prescribing CEFOTAN<span class="Sup"></span>in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> of a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>As with other broad-spectrum antibiotics, prolonged use of CEFOTAN may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> does occur during therapy, appropriate measures should be taken.</p>
<p>CEFOTAN should be used with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients should be counseled that antibacterial drugs, including CEFOTAN<span class="Sup"></span>, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (eg, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When CEFOTAN<span class="Sup"></span>is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by CEFOTAN<span class="Sup"></span>or other antibacterial drugs in the future.</p>
<p>As with some other cephalosporins, a disulfiram-like reaction characterized by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> may occur when alcohol (beer, wine, etc.) is ingested within 72 hours after CEFOTAN administration. Patients should be cautioned about the ingestion of alcoholic beverages following the administration of CEFOTAN.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Increases in serum creatinine have occurred when CEFOTAN was given alone. If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may be potentiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">The administration of CEFOTAN may result in a false positive reaction for glucose in the urine using Clinitest<span class="Sup">Â®</span>â€¡, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase be used.</p>
<p>As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by JaffeÂ´ reaction and produce false increases in the levels of creatinine reported.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Although long-term studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic potential of cefotetan was found in standard laboratory tests.</p>
<p>Cefotetan has adverse effects on the testes of prepubertal rats. Subcutaneous administration of 500 mg/kg/day (approximately 8-16 times the usual adult human dose) on days 6-35 of life (thought to be developmentally analogous to late childhood and prepuberty in humans) resulted in reduced testicular weight and seminiferous tubule degeneration in 10 of 10 animals. Affected cells included spermatogonia and spermatocytes; Sertoli and Leydig cells were unaffected. Incidence and severity of lesions were dose-dependent; at 120 mg/kg/day (approximately 2-4Â times the usual human dose) only 1 of 10 treated animals was affected, and the degree of degeneration was mild.</p>
<p>Similar lesions have been observed in experiments of comparable design with other methylthiotetrazole-containing antibiotics and impaired fertility has been reported, particularly at high dose levels. No testicular effects were observed in 7-week-old rats treated with up to 1000 mg/kg/day SC for 5 weeks, or in infant dogs (3 weeks old) that received up to 300Â mg/kg/day IV for 5 weeks. The relevance of these findings to humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.6"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.6.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects: Pregnancy Category B:</span></h3>
<p class="First">Reproduction studies have been performed in rats and monkeys at doses up to 20 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefotetan. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Cefotetan is excreted in human milk in very low concentrations. Caution should be exercised when cefotetan is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.9"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Of the 925 subjects who received cefotetan in clinical studies, 492 (53%) were 60 years and older, while 76 (8%) were 80 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <a href="#barberpj1136224293579">DOSAGE AND ADMINISTRATION</a>âˆ’ <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="barberpj1136224399158"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In clinical studies, the following adverse effects were considered related to CEFOTAN therapy. Those appearing in italics have been reported during postmarketing experience.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Gastrointestinal: </h2>
<p class="First">Symptoms occurred in 1.5% of patients, the most frequent were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 80) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1 in 700); <span class="Italics"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span></span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment or surgical prophylaxis. (See <a href="#barberpj1136224340751">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Hematologic:</h2>
<p class="First">Laboratory abnormalities occurred in 1.4% of patients and included <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (1 in 200), positive direct Coombsâ€™ test (1 in 250), and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> (1 in 300); <span class="Italics"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, </span>and <span class="Italics">prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with or without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Hepatic: </h2>
<p class="First">Enzyme elevations occurred in 1.2% of patients and included a rise in ALT (SGPT) (1 in 150), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (1Â in 300), alkaline phosphatase (1 in 700), and LDH (1Â inÂ 700).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </h2>
<p class="First">Reactions were reported in 1.2% of patients and included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1 in 150) and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (1 in 700); <span class="Italics"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>Local:</h2>
<p class="First">Effects were reported in less than 1% of patients and included <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> at the site of injection (1 in 300), and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (1 in 500).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>Renal:</h2>
<p class="First">Elevations in BUN and serum creatinine have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2>Urogenital:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has rarely been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8"></a><p></p>
<h2>Miscellaneous:<span class="Bold Italics"></span>
</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></p>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with cefotetan, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, aplastic  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, elevated bilirubin, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, when the dosage was not reduced. (See <a href="#barberpj1136224293579">DOSAGE AND ADMINISTRATION</a>and <a href="#barberpj1136224689876">OVERDOSAGE</a>.) If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="barberpj1136224689876"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Information on overdosage with CEFOTAN in humans is not available. If overdosage should occur, it should be treated symptomatically and hemodialysis considered, particularly if renal function is compromised.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="barberpj1136224293579"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Treatment</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Cefotetan injection in Galaxy<span class="Bold"><span class="Sup">Â®</span></span> plastic container should not be used for intramuscular administration.</h2>
<p class="First">CEFOTAN in the ADD-Vantage Vial is intended for intravenous infusion only, after dilution with the appropriate volume of ADD-Vantage diluent solution.</p>
<p>The usual adult dosage is 1 or 2 grams of CEFOTAN (cefotetan disodium for injection) administered intravenously or intramuscularly or CEFOTAN (cefotetan injection) in the Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) administered intravenously every 12 hours for 5 to 10 days. Proper dosage and route of administration should be determined by the condition of the patient, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism.</p>
<table frame="hsides">
<caption><span> General Guidelines for Dosage of CEFOTAN</span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td valign="top"><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p></td>
<td valign="top"><p class="First"><span class="Bold">Daily Dose</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Frequency and Route</span></p></td>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3" valign="top"></td></tr>
<tr class="Last"><td colspan="3" valign="top"></td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>
<span class="Italics">Klebsiella pneumoniae</span> skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> should be treated with 1 or 2 grams every 12 hours IV or IM.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€ </a></dt>
<dd> Maximum daily dosage should not exceed 6 grams.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td valign="top"><p class="First">Urinary Tract</p></td>
<td valign="top"><p class="First">1-4 grams</p></td>
<td valign="top">
<p class="First">500 mg every 12 hours IV or IM</p>
<p>1 or 2 g every 24 hours IV or IM</p>
<p>1 or 2 g every 12 hours IV or IM</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Skin &amp; Skin Structure</p>
<p>	Mild -Â Moderate<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p>
</td>
<td valign="top"><p class="First">2 grams</p></td>
<td valign="top">
<p class="First">2 g every 24 hours IV</p>
<p>1 g every 12 hours IV or IM</p>
</td>
</tr>
<tr>
<td valign="top"><p class="First">Severe</p></td>
<td valign="top"><p class="First">4 grams</p></td>
<td valign="top"><p class="First">2 g every 12 hours IV</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Other Sites</p></td>
<td valign="top"><p class="First">2 -Â 4 grams</p></td>
<td valign="top"><p class="First">1 or 2 g every 12 hours IV or IM</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Severe</p></td>
<td valign="top"><p class="First">4 grams</p></td>
<td valign="top"><p class="First">2 g every 12 hours IV</p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">Life-Threatening</p></td>
<td valign="top"><p class="First">6 grams<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€ </a></p></td>
<td valign="top"><p class="First">3 g every 12 hours IV</p></td>
</tr>
</tbody>
</table>
<p>If <span class="Italics">Chlamydia trachomatis</span> is a suspected pathogen in gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, appropriate antichlamydial coverage should be added, since cefotetan has no activity against this organism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Prophylaxis:</h2>
<p class="First">To prevent <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in clean contaminated or potentially contaminated surgery in adults, the recommended dosage is 1 or 2 g of CEFOTAN administered once, intravenously, 30 to 60 minutes prior to surgery. In patients undergoing cesarean section, the dose should be administered as soon as the umbilical cord is clamped.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">When renal function is impaired, a reduced dosage schedule must be employed. The following dosage guidelines may be used.</p>
<table frame="hsides">
<caption><span> DOSAGE GUIDELINES FOR PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span></span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td valign="top">
<p class="First"><span class="Bold">Creatinine</span></p>
<p><span class="Bold">Clearance</span></p>
<p><span class="Bold">mL/min</span></p>
</td>
<td valign="top"><p class="First"><span class="Bold">Dose</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Frequency</span></p></td>
</tr></thead>
<tfoot>
<tr class="First Last"><td colspan="3" valign="top"></td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Dose determined by the type and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td valign="top"><p class="First">&gt;30</p></td>
<td valign="top"><p class="First">Usual Recommended Dosage<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td>
<td valign="top"><p class="First">Every 12 hours</p></td>
</tr>
<tr>
<td valign="top"><p class="First">10Â -Â 30</p></td>
<td valign="top"><p class="First">Usual Recommended Dosage<a href="#footnote-6" class="Sup">*</a></p></td>
<td valign="top"><p class="First">Every 24 hours</p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">&lt;10</p></td>
<td valign="top"><p class="First">Usual Recommended Dosage<a href="#footnote-6" class="Sup">*</a></p></td>
<td valign="top"><p class="First">Every 48 hours</p></td>
</tr>
</tbody>
</table>
<p>Alternatively, the dosing interval may remain constant at 12Â hour intervals, but the dose reduced to one-half the usual recommended dose for patients with a creatinine clearance of 10-30 mL/min, and one-quarter the usual recommended dose for patients with a creatinine clearance of less than 10Â mL/min.</p>
<p>When only serum creatinine levels are available, creatinine clearance may be calculated from the following formula. The serum creatinine level should represent a steady state of renal function.</p>
<p>Males:	<span class="Underline">Weight (kg) x (140 - age)	</span></p>
<p>	72 x serum creatinine (mg/100 mL)</p>
<p>Females:	0.9 x value for males</p>
<p>Cefotetan is dialyzable and it is recommended that for patients undergoing intermittent hemodialysis, one-quarter of the usual recommended dose be given every 24 hours on days between dialysis and one-half the usual recommended dose on the day of dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold Italics">CEFOTETAN DISODIUM FOR INJECTION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Preparation of Solution From Cefotetan Disodium For Injection:</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>For Intravenous Use:</h2>
<p class="First">Reconstitute with Sterile Water for Injection. Shake to dissolve and let stand until clear.</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td valign="top"><p class="First"><span class="Bold">Vial Size</span></p></td>
<td valign="top">
<p class="First"><span class="Bold">Amount of</span></p>
<p><span class="Bold">Diluent</span></p>
<p><span class="Bold">Added</span></p>
<p><span class="Bold">(mL)</span></p>
</td>
<td valign="top">
<p class="First"><span class="Bold">Approximate</span></p>
<p><span class="Bold">Withdrawable</span></p>
<p><span class="Bold">Vol (mL)</span></p>
</td>
<td valign="top">
<p class="First"><span class="Bold">Approximate</span></p>
<p><span class="Bold">Average</span></p>
<p><span class="Bold">Concentration</span></p>
<p><span class="Bold">(mg/mL)</span></p>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top"><p class="First">1 gram</p></td>
<td valign="top"><p class="First">10</p></td>
<td valign="top"><p class="First">10.5</p></td>
<td valign="top"><p class="First">95</p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">2 grams</p></td>
<td valign="top"><p class="First">10-20</p></td>
<td valign="top"><p class="First">11-21</p></td>
<td valign="top"><p class="First">182-95</p></td>
</tr>
</tbody>
</table>
<p>Infusion bottles (100 mL) may be reconstituted with 50 to 100 mL of Dextrose Injection 5% or Sodium Chloride Injection 0.9%.</p>
<p><span class="Bold">NOTE:</span> ADD-VANTAGE VIALS ARE NOT TO BE USED IN THIS MANNER</p>
<p><span class="Bold">For ADD-Vantage Vials:</span> ADD-Vantage Vials of CEFOTAN are to be reconstituted only with Sodium Chloride Injection 0.9% or Dextrose Injection 5% in the 50 mL, 100 mL or 250 mL Flexible Diluent Containers. CEFOTAN supplied in single-use ADD-Vantage Vials should be prepared as directed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="barberpj1136224261220"></a><a name="section-12.3"></a><p></p>
<h2>Directions for Use of CEFOTAN (cefotetan disodium for injection) in ADD-Vantage Vials:</h2>
<p class="First"><span class="Bold">To Open Diluent Container:</span> Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4"></a><p></p>
<h2>To Assemble ADD-Vantage Vial and Flexible Diluent Container: (Use Aseptic Technique)</h2>
<p class="First"><span class="Bold">1</span>.	Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-1.jpg"></div>
<p>To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (See <a href="#barberpj1136223968783">Figure 1</a>), then pull straight up to remove the cap. (See <a href="#barberpj1136223996673">Figure 2</a>.) </p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-2.jpg"></div>
<p><span class="Bold">NOTE:</span> Once the breakaway cap has been removed, do not access vial with syringe.</p>
<p>b.	To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (See <a href="#barberpj1136224027345">Figure 3</a>.)</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-3.jpg"></div>
<p><span class="Bold">2.</span>	Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180Â°) after the first audible click. (See <a href="#barberpj1136224051829">Figure 4</a>.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. <span class="Bold">NOTE:</span> ONCE VIAL IS SEATED, DO NOT ATTEMPT TO REMOVE. (See <a href="#barberpj1136224051829">Figure 4.</a>).</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-4.jpg"></div>
<p><span class="Bold">3</span>.	Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.</p>
<p><span class="Bold">4.</span>	Label appropriately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.5"></a><p></p>
<h2>To Prepare Admixture:</h2>
<p class="First"><span class="Bold">1</span>.	Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.</p>
<p><span class="Bold">2.</span>	With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (See <a href="#barberpj1136224128267">Figure 5</a>.)</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-5.jpg"></div>
<p><span class="Bold">3.</span>	Pull the inner cap from the drug vial. (See <a href="#barberpj1136224142501">Figure 6</a>.) Verify that the rubber stopper has been pulled out and invert the system several times, allowing the drug and diluent to mix.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56912A83-4CBA-4461-D983-3A0656515458&amp;name=cefotan-fig-6.jpg"></div>
<p>4.	Mix contents thoroughly and use within the specified time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.6"></a><p></p>
<h2>Preparation For Administration: (Use Aseptic</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.7"></a><p></p>
<h2>Technique)</h2>
<p class="First"><span class="Bold">1.</span>	Confirm the activation and admixture of vial contents.</p>
<p><span class="Bold">2.</span>	Check for leaks by squeezing container firmly. If leaks are found, discard unit as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p><span class="Bold">3.</span>	Close flow control clamp of administration set.</p>
<p><span class="Bold">4.</span>	Remove cover from outlet port at bottom of container.</p>
<p><span class="Bold">5</span>.	Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.</p>
<p><span class="Bold">NOTE: </span>See full directions on administration set carton.</p>
<p><span class="Bold">6.</span>	Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.</p>
<p><span class="Bold">7.</span>	Squeeze and release drip chamber to establish proper fluid level in chamber.</p>
<p><span class="Bold">8</span>.	Open flow control clamp and clear air from set. Close clamp.</p>
<p><span class="Bold">9.</span>	Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.</p>
<p></p>
<p><span class="Bold">10</span>.	Regulate rate of administration with flow control clamp.</p>
<p><span class="Bold">WARNING:</span><span class="Bold">Do not use flexible container in series connections.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.8"></a><p></p>
<h2>For Intramuscular Use:</h2>
<p class="First">Reconstitute with Sterile Water for Injection; Bacteriostatic Water for Injection; Sodium Chloride Injection 0.9%, USP; 0.5% Lidocaine HCl; or 1% Lidocaine HCl. Shake to dissolve and let stand until clear.</p>
<table frame="hsides">
<caption><span></span></caption>
<colgroup>
<col>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td valign="top">
<p class="First"><span class="Bold">Vial</span></p>
<p><span class="Bold">Size</span></p>
</td>
<td valign="top">
<p class="First"><span class="Bold">Amount of</span></p>
<p><span class="Bold">Diluent</span></p>
<p><span class="Bold">Added</span></p>
<p><span class="Bold">(mL)</span></p>
</td>
<td valign="top">
<p class="First"><span class="Bold">Approximate</span></p>
<p><span class="Bold">Withdrawable</span></p>
<p><span class="Bold">Vol (mL)</span></p>
</td>
<td valign="top">
<p class="First"><span class="Bold">Approximate</span></p>
<p><span class="Bold">Average Concentration</span></p>
<p><span class="Bold">(mg/mL)</span></p>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top"><p class="First">1 gram</p></td>
<td valign="top"><p class="First">2</p></td>
<td valign="top"><p class="First">2.5</p></td>
<td valign="top"><p class="First">400</p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">2 grams</p></td>
<td valign="top"><p class="First">3</p></td>
<td valign="top"><p class="First">4</p></td>
<td valign="top"><p class="First">500</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.9"></a><p></p>
<h2>Intravenous Administration</h2>
<p class="First">The intravenous route is preferable for patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p>For intermittent intravenous administration, a solution containing 1 gram or 2 grams of CEFOTAN (cefotetan disodium for injection) in Sterile Water for Injection can be injected over a period of three to five minutes. Using an infusion system, the solution may also be given over a longer period of time through the tubing system by which the patient may be receiving other intravenous solutions. ButterflyÂ® or scalp vein-type needles are preferred for this type of infusion. However, during infusion of the solution containing CEFOTAN (cefotetan disodium for injection), it is advisable to discontinue temporarily the administration of other solutions at the same site.</p>
<p><span class="Bold">NOTE:</span> Solutions of CEFOTAN must not be admixed with solutions containing aminoglycosides. If CEFOTAN and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.</p>
<p><span class="Bold">Intramuscular Administration</span></p>
<p>As with all intramuscular preparations, CEFOTAN (cefotetan disodium for injection) should be injected well within the body of a relatively large muscle such as the upper outer quadrant of the buttock (ie, gluteus maximus); <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> is necessary to avoid inadvertent injection into a blood vessel.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1>CEFOTETAN INJECTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>Directions for Use of CEFOTAN (cefotetan injection) in Galaxy<span class="Bold"><span class="Sup">Â®</span></span> Plastic Container (PL 2040)</h2>
<p class="First">CEFOTAN (cefotetan injection) in Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) is for intravenous administration only.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store in a freezer capable of maintaining a temperature of -20Â°C/-4Â°F.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>Thawing of Plastic Container:</h2>
<p class="First">Thaw frozen container at room temperature (25Â°C/77Â°F) or in a refrigerator (5Â°C/41Â°F). <span class="Bold">[DO NOT FORCE THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.]</span></p>
<p>Check for minute leaks by squeezing container firmly. If leaks are detected, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p>The container should be visually inspected. Components of the solution may precipitate in the frozen state and will dissolve upon reaching room temperature with little or no <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. Potency is not affected. Agitate after solution has reached room temperature. If after visual inspection the solution remains cloudy or if an insoluble precipitate is noted or if any seals or outlet ports are not intact, the container should be discarded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<h2>Preparation of Intravenous Use (Use aseptic technique):</h2>
<p class="First">1.	Suspend container from eyelet support.</p>
<p>2.	Remove protector from outlet port at bottom of container.</p>
<p>3.	Attach administration set. Refer to complete directions accompanying set.</p>
<p><span class="Bold">Caution:</span> Do not use plastic containers in series connections. Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.5"></a><p></p>
<h2>Intravenous Administration</h2>
<p class="First">The intravenous route is preferable for patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p>Using an infusion system, CEFOTAN (cefotetan injection) in Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) should be given over 20 to 60 minutes through the tubing system by which the patient may be receiving other intravenous solutions. Butterfly<span class="Sup">Â®</span> or scalp vein-type needles are preferred for this type of infusion. However, during infusion of the solution containing CEFOTAN (cefotetan injection) in Galaxy<span class="Sup">Â®</span> plastic container (PL 2040), it is advisable to discontinue temporarily the administration of other solutions at the same site.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6"></a><p></p>
<h2>Compatibility and Stability of CEFOTAN Products</h2>
<p class="First">Frozen samples should be thawed at room temperature before use. After the periods mentioned below, any unused solutions or frozen material should be discarded. <span class="Bold">DO NOT REFREEZE</span>.</p>
<p><span class="Bold">NOTE:  </span>Solutions of CEFOTAN must not be admixed-with solutions containing aminoglycosides. If CEFOTAN and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection. <span class="Bold">DO NOT ADD SUPPLEMENTARY MEDICATION</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6.1"></a><p></p>
<h3><span class="Bold Italics">CEFOTEAN DISODIUM FOR INJECTION</span></h3>
<p class="First">CEFOTAN (cefotetan disodium for injection) reconstituted as described above (PREPARATION OF SOLUTION) maintains satisfactory potency for 24 hours at room temperature (25Â°C/77Â°F), for 96 hours under refrigeration (5Â°C/41Â°F), and for at least 1 week in the frozen state (-20Â°C/-4Â°F). After reconstitution and subsequent storage in disposable glass or plastic syringes, CEFOTAN (cefotetan disodium for injection) is stable for 24 hours at room temperature and 96 hours under refrigeration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.7"></a><p></p>
<h2>ADD-Vantage Vials</h2>
<p class="First">Ordinarily, ADD-Vantage Vials should be reconstituted only when it is certain that the patient is ready to receive the drug. However, ADD-Vantage Vials of CEFOTAN reconstituted as described in Preparation of Solution, for ADD-Vantage Vials, maintains satisfactory potency for 24Â hours at room temperature (25Â°C/77Â°F).</p>
<p>(DO NOT REFRIGERATE OR FREEZE CEFOTAN IN ADD-VANTAGE VIALS.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1>CEFOTETAN INJECTION</h1>
<p class="First">The thawed solution in Galaxy<span class="Sup">Â®</span> plastic container (PLÂ 2040) remains chemically stable for 48 hours at room temperature (25Â°C/77Â°F) or for 21 days under refrigeration (5Â°C/41Â°F).</p>
<p><span class="Bold">NOTE:</span> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CEFOTAN (cefotetan disodium for injection) is a dry, white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder supplied in vials containing cefotetan disodium equivalent to 1 g and 2 g cefotetan activity for intravenous and intramuscular administration. The vials should not be stored at temperatures above 22Â°C (72Â°F) and should be protected from light.</p>
<p>1 g ADD-Vantage Vial (NDC 0310-0376-31)</p>
<p>2 g ADD-Vantage Vial (NDC 0310-0377-32)</p>
<p>1 g Vial (NDC 0310-0376-10)</p>
<p>2 g Vial (NDC 0310-0377-20)</p>
<p>1 g Piggyback Vial (NDC 0310-0376-11)</p>
<p>2 g Piggyback Vial (NDC 0310-0377-21)</p>
<p>CEFOTAN is also available as a 10 g pharmacy bulk package.</p>
<p>10 g in 100 mL Vial (NDC 0310-0375-10)</p>
<p>CEFOTAN (cefotetan injection) is supplied as a frozen, iso-osmotic, premixed solution in single dose Galaxy<span class="Sup">Â®</span> plastic containers (PL 2040) as follows:</p>
<p>1 g in 50 mL plastic container (NDC 0310-0378-51)</p>
<p>2 g in 50 mL plastic container (NDC 0310-0379-51)</p>
<p>Store containers at or below -20Â°C/-4Â°F. <span class="Bold">[See <a href="#barberpj1136224261220">DIRECTIONS FOR USE OF CEFOTAN (cefotetan injection</a>) IN GALAXYÂ® PLASTIC CONTAINER (PLÂ 2040)].</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-16"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1.	National Committee for Clinical Laboratory Standards. <span class="Underline">Methods for Dilution Antimicrobial</span><span class="Underline">Susceptibility Tests for Bacteria that Grow Aerobically</span> -- Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December, 1993.</p>
<p>2.	National Committee for Clinical Laboratory Standards. <span class="Underline">Performance Standards for Antimicrobial</span><span class="Underline">Disk Susceptibility Tests</span> -- Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993.</p>
<p>National Committee for Clinical Laboratory Standards. <span class="Underline">Methods for Antimicrobial Susceptibility</span><span class="Underline">Testing of Anaerobic Bacteria</span> - Third Edition. Approved Standard NCCLS Document M11-A3, Vol 13, No. 26, NCCLS, Villanova, PA, December 1993.</p>
<p>*Galaxy<span class="Sup">Â®</span> is a registered trademark of Baxter Healthcare Corporation.</p>
<p>â€ ADD-Vantage is a registered trademark of Abbott Laboratories Inc.</p>
<p>â€¡Clinitest<span class="Sup">Â®</span>  is a registered trademark of Ames Division, Miles Laboratories, Inc.</p>
<p>All other trademarks are the property of the AstraZeneca group of companies.</p>
<p><span class="Sup">Â©</span> AstraZeneca 2002, 2004</p>
<p>CEFOTAN<span class="Sup">Â®</span> (cefotetan injection) in Galaxy<span class="Sup">Â®</span> plastic container (PL 2040) is manufactured by Baxter Healthcare Corporation, Deerfield, Illinois 60015 USA for AstraZeneca Pharmaceuticals LP.</p>
<p>CEFOTAN<span class="Sup">Â®</span> (cefotetan disodium for injection) is manufactured by GlaxoSmithKline for:</p>
<p>AstraZeneca Pharmaceuticals LP,  Wilmington, DE 19850</p>
<p>Rev 01/04 SIC 64173-03</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTANÂ 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0376</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefotetan disodium</strong> (Cefotetan) </td>
<td class="formItem"></td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>dextrose anhydrous</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0376-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-0376-11</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, PIGGYBACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0310-0376-31</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTANÂ 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0377</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefotetan disodium</strong> (Cefotetan) </td>
<td class="formItem"></td>
<td class="formItem">2Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>dextrose anhydrous</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0377-20</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-0377-21</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, PIGGYBACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0310-0377-32</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0310-0377-62</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTANÂ 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0375</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefotetan disodium</strong> (Cefotetan) </td>
<td class="formItem"></td>
<td class="formItem">10Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>dextrose anhydrous</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0375-10</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, PHARMACY BULK PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-0375-61</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, PHARMACY BULK PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTANÂ 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0378</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefotetan disodium</strong> (Cefotetan) </td>
<td class="formItem"></td>
<td class="formItem">1Â g Â inÂ 50Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid </strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0378-51</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTANÂ 		
					</strong><br><span class="contentTableReg">cefotetan disodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0379</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefotetan disodium</strong> (Cefotetan) </td>
<td class="formItem"></td>
<td class="formItem">2Â g Â inÂ 50Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid </strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0379-51</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AstraZeneca Pharmaceuticals, LP</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>56912A83-4CBA-4461-D983-3A0656515458</div>
<div>Set id: 56912A83-4CBA-4461-D983-3A0656515458</div>
<div>Version: 1</div>
<div>Effective Time: 20060407</div>
</div>
</div>Â <div class="DistributorName">AstraZeneca Pharmaceuticals, LP</div></p>
</body></html>
